Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2790 participants.
Also called NCT01681381
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 2,790 participants
- Sponsor
- Essen Technology (Beijing) Co., Ltd.
- Registry
-
NCT01681381
-
- Other papers using this trial's data
- A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents
- Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01681381. Randomized; no masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2013-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
- Condition
- Ischemic Heart Disease
- Condition
- Myocardial Ischemia
- Condition
- Coronary Artery Lesions,Primary
- Condition
- Coronary Disease
- Condition
- Acute Coronary Syndrome
- Condition
- Furcation Lesion of Coronary Artery
- Intervention (Device)
- Tivoli® DES
- Intervention (Device)
- Firebird2® DES
- Lead sponsor
- Essen Technology (Beijing) Co., Ltd.
Record details
- Record id
cardio:ct-nct01681381- Content hash
8c5270dc79b747a2b959fc4c13ca465786b76e893ce7df47259b49559df2f510